Cyclica leverages artificial intelligence and computational biophysics to reshape the drug discovery process.

Cyclica's proprietary structure-based and AI-augmented drug discovery platform include Ligand Design for multi-targeted and multi-objective drug design and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights. Taken together Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. 

By doing more with artificial intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.